BioMarin to Participate in Upcoming Investor Conferences
BioMarin (BMRN) will present at several healthcare investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Citi and Morgan Stanley.
Rhea-AI Summary
BioMarin (BMRN) will present at several healthcare investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Citi and Morgan Stanley. Presentations take place between September 9 and 14, 2026, at specified times in Eastern Time.
Live audio webcasts and limited-time archives of BioMarin’s remarks will be accessible through the company’s investor relations website at https://investors.biomarin.com/. The company describes itself as a global rare disease biotechnology firm with nine commercial therapies and an active clinical and preclinical pipeline.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST
- Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST
- Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST
- Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael,
To learn more, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-upcoming-investor-conferences-302866797.html
SOURCE BioMarin Pharmaceutical Inc.